Tempus reported a Q2 revenue lift driven by strong oncology testing momentum and raised full-year 2026 revenue guidance. The company said oncology testing revenue grew 31% year over year, contributing to overall quarterly revenue up 22% to $382.5 million, as US Food and Drug Administration approvals supported commercialization. Tempus tied the outlook to regulatory momentum for its xT CDx tumor-only indication for next-generation sequencing, alongside the ongoing review of its xF liquid biopsy test. Management also reaffirmed that its minimal residual disease strategy is set to accelerate following its planned acquisition of Personalis for about $1.7 billion, positioning MRD as a longer-term growth driver. CEO Eric Lefkofsky and CFO Jim Rogers framed the acquisition as a portfolio and adoption catalyst, aiming to strengthen clinical study execution and improve commercialization of MRD testing. The company’s call also addressed deal-close confidence after investor questions about potential termination risk.